Intelligent Liver Function Testing: Working Smarter to Improve Patient Outcomes in Liver Disease
Open Access
- 1 September 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 5 (5), 1090-1100
- https://doi.org/10.1093/jalm/jfaa109
Abstract
Chronic liver disease (CLD) is a significant health problem affecting millions of people worldwide. In Scotland, CLD is a major cause of premature mortality. Liver function tests (LFTs) are a panel of frequently requested blood tests which may indicate liver disease. However, LFTs commonly contain at least one abnormal result, and abnormalities are rarely investigated to the extent recommended by national guidelines. The intelligent Liver Function Testing (iLFT) pathway is a novel, automated system designed to improve early diagnosis of liver disease. Initial abnormal LFT results trigger a cascade of reflexive testing to help identify the cause of any liver dysfunction. Algorithms combine these results with demographic and clinical data (such as patient age, body mass index, and alcohol intake) and fibrosis estimates to produce an electronic diagnosis and management plan. The pilot trial demonstrated that iLFT increased diagnosis of liver disease whilst remaining cost-effective. As such, iLFT has been fully operational across our region (NHS Tayside, Scotland) since August 2018. In the first year, iLFT generated over 2000 diagnoses from 1824 patient samples with an abnormality in the initial LFTs. The majority of these patients could be safely managed in primary care. iLFT allows maximal value to be obtained from liver blood tests across biochemistry, virology, immunology, and hematology with only minor changes to working practices. ‘Intelligent’, algorithm-led testing pathways break down the barrier between clinical and laboratory medicine and offer solutions to many of the challenges experienced in modern healthcare systems.Keywords
Funding Information
- CSO Scottish Government
This publication has 18 references indexed in Scilit:
- Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysisBMC Medicine, 2014
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohortJournal of Hepatology, 2012
- Upper limits of normal for alanine aminotransferase activity in the United States populationHepatology, 2011
- Reduced Mortality Rates Following Elective Percutaneous Liver BiopsiesGastroenterology, 2010
- Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histologyHepatology, 2009
- Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE)Health Technology Assessment, 2009
- The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLDHepatology, 2007
- Serum markers detect the presence of liver fibrosis: A cohort studyGastroenterology, 2004
- Liver BiopsyThe New England Journal of Medicine, 2001